The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension

François Haddad, MD; Kevin Contrepois, PhD; Myriam Amsallem, MD, PhD; Andre Y. Denault, MD, PhD; Roberto J. Bernardo, MD; Alokkumar Jha, PhD; Shalina Taylor, PhD; Jennifer Arthur Ataam, PhD; Olaf Mercier, MD, PhD; Tatiana Kuznetsova, MD, PhD; Anton Vonk Noordegraaf, MD, PhD; Roham T. Zamanian, MD; and Andrew J. Sweatt, MD

BACKGROUND: Prognosis in pulmonary arterial hypertension (PAH) is closely related to indexes of right ventricular function. A better understanding of their relationship may provide important implications for risk stratification in PAH.

RESEARCH QUESTION: Can clinical network graphs inform risk stratification in PAH?

STUDY DESIGN AND METHODS: The study cohort consisted of 231 patients with PAH followed up for a median of 7.1 years. An undirected, correlation network was used to visualize the relationship between clinical features in PAH. This network was enriched for right heart parameters and included N-terminal pro-hormone B-type natriuretic peptide (NT-proBNP), comprehensive echocardiographic parameters, and hemodynamics, as well as 6-min walk distance (6MWD), vital signs, laboratory data, and diffusing capacity for carbon monoxide (DLCO). Connectivity was assessed by using eigenvector and betweenness centrality to reflect global and regional connectivity, respectively. Cox proportional hazards regression was used to model event-free survival for the combined end point of death or lung transplantation.

RESULTS: A network of closely intertwined features centered around NT-proBNP with 6MWD emerging as a secondary hub were identified. Less connected nodes included DLCO, systolic BP, albumin, and sodium. Over the follow-up period, death or transplantation occurred in 92 patients (39.8%). A strong prognostic model was achieved with a Harrell’s C-index of 0.81 (0.77-0.85) when combining central right heart features (NT-proBNP and right ventricular end-systolic remodeling index) with 6MWD and less connected nodes (DLCO, systolic BP, albumin, sodium, sex, connective tissue disease etiology, and prostanoid therapy). When added to the baseline risk model, serial change in NT-proBNP significantly improved outcome prediction at 5 years (increase in C-statistic of 0.071 ± 0.024; P = .003).

INTERPRETATION: NT-proBNP emerged as a central hub in the intertwined PAH network. Connectivity analysis provides explainability for feature selection and combination in outcome models.

KEY WORDS: cardiovascular imaging; graph theory; pulmonary arterial hypertension; pulmonary hypertension; right heart failure; risk stratification; unsupervised learning

ABBREVIATIONS: 6MWD = 6-min walk distance; BNP = B-type natriuretic peptide; CTD = connective tissue disease; DLCO = diffusing capacity of the lung for carbon monoxide; eRAP = estimated right atrial pressure; GFR = glomerular filtration rate; MPAP = mean pulmonary arterial pressure; NT-proBNP = N-terminal pro-B type natriuretic peptide; PAH = pulmonary arterial hypertension; PVR = pulmonary vascular resistance; PVRr = relative pulmonary vascular resistance; RV = right ventricular; RVEF = right ventricular ejection fraction; RVL = right ventricular longitudinal strain; RVSP = right ventricular systolic pressure; TAPSE = tricuspid annular plane systolic excursion; TR = tricuspid regurgitation

CHEST 2022; 161(5):1347-1359

FOR EDITORIAL COMMENT, SEE PAGE 1138
Survival in pulmonary arterial hypertension (PAH) is closely associated with right heart failure.1-6 In the multicenter National Institutes of Health registry of D’Alonzo et al,1 right heart failure accounted for more than two-thirds of deaths, and both right atrial pressure and cardiac index emerged as strong predictors of outcome. Since then, large registry studies have refined risk prediction in PAH by incorporating B-type natriuretic peptide (BNP) or its N-terminal pro-hormone (NT-proBNP), functional class, and other selected clinical or laboratory data.2-7 These registries include the French Pulmonary Hypertension Network (FPHN), the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL), and the Pulmonary Hypertension Outcomes Risk Assessment (PHORA) prediction models.2-6 In parallel to these registry-based scores, much attention has been focused on identified imaging predictors of outcome.6 Several right heart metrics have been considered, including tricuspid annular plane systolic excursion (TAPSE), right ventricular (RV) longitudinal strain (RVLS), RV ejection fraction, RV end-systolic dimension or remodeling indexes, and, more recently, right atrial volume or right atrial reservoir function.9-13 Interpreting imaging studies in PAH is sometimes challenging in view of the multiplicity of indexes and variable coverage among studies (Fig 1A). In fact, many studies focus on a specific right heart metric with little consideration given to the strong associations that exist between them. A better understanding of these relationships may provide valuable insights for risk stratification models. In recent years, graph theory has emerged as a powerful tool to model pairwise relationships between nodes or features.14 Network graphs are commonly used in social sciences or molecular biology and increasingly used in clinical medicine.15,16 They provide a method for visualizing data architecture and identifying central features as well as potential complementarity between parameters (Fig 1B). For example, a study by Oldham et al16 used network graphs to identify key features of invasive cardiopulmonary exercise testing, which were then used to identify clinically relevant clusters.

The main objective of the current study was to model data architecture in PAH by using network graphs. We used a dataset that was enriched for right heart parameters as well as comprehensive clinical and laboratory data. Our first objective was to use network graphs to visualize and quantify feature connectivity in PAH. Our second objective was to determine by what extent connectivity is related to all-cause mortality or lung transplantation in PAH. The final objective was to determine how connectivity in PAH informs risk stratification models.

Study Design and Methods

Study Population

Consecutive patients with PAH followed up at Stanford University between November 2008 and March 2014 were considered for inclusion in the study. The diagnosis of PAH was based on a resting mean pulmonary arterial pressure (MPAP) ≥ 25 mm Hg, pulmonary arterial wedge pressure ≤ 15 mm Hg, and pulmonary vascular resistance (PVR) > 240 dynes·s/cm² (3 Wood units) based...
on the definition at the time of enrollment in the registry. An echocardiogram was required for inclusion in the study as well as an NT-proBNP laboratory value. Patients with congenital heart disease (n = 14), porto-pulmonary hypertension (n = 18), or with a clinical diagnosis of moderate to severe chronic obstructive or restrictive lung disease (n = 12) were excluded. The final cohort consisted of 231 patients, with the majority of patients having prevalent PAH (n = 175 [76%]). The study was approved by the Stanford Institutional Review Board (IRB #14083) and conducted in agreement with the Declaration of Helsinki seventh revision (2013).

### Clinical Data Collection

Clinical data included demographic characteristics, anthropomorphic measures, etiology of PAH, right heart catheterization data, echocardiography. Only a few variables required imputations (eg, red blood cell distribution [n = 2], 6MWD [n = 4], and DLCO [n = 27]).

### Quantitative Echocardiography

Studies were acquired by using a Philips iE33 ultrasound system and analyzed according to the American Society of Echocardiography recommendations by a cardiologist blinded to the clinical outcome (M. A.). A focused apical four-chamber right ventricular view was used to measure parameters of right atrial and right ventricular size and function. Measures included RV end-systolic remodeling index (RVESRI), RV longitudinal strain (RVLS), RV fractional area change, TAPSE by a two-dimensional method, RV areas including relative RV to left ventricular area, right atrial volume, left ventricular eccentricity index, left ventricular ejection fraction, estimated RV systolic pressure (RVSP), and estimated right atrial pressure (eRAP). RVESRI was measured as previously described as the ratio of RV lateral length to septal length, and it represents an internally scaled end-systolic dimension parameter. The eRAP was determined according to the French Pulmonary Hypertension Network (FPHN), and the World Symposium of Pulmonary Hypertension score.

### Right Heart Catheterization

Using an internal jugular or femoral vein approach, RAP, pulmonary arterial pressures (systolic, mean [MPAP], and diastolic pressure) and pulmonary capillary wedge pressure were measured. Cardiac output was derived by using the indirect Fick method and assumed oxygen consumption. PVR was indexed to body surface area, and relative PVR (PVRr) was measured as the ratio of PVR and systemic vascular resistance.

### Statistical Methods

Baseline characteristics are presented as median and interquartile range for continuous variables, and categorical variables are presented as number and percentage. To construct the correlation network, pairwise Spearman rank correlations were calculated by using the R package Hmisc (version 4.4-0), and undirected networks were plotted with igraph (version 1.2.5). Only pairwise correlations with Bonferroni-adjusted P values < .05 were included and displayed via the Fruchterman-Reingold method (supplementary document additional statistical explanation section). We selected the Spearman correlation rather than the Pearson correlation because it is better suited to model monotonic nonlinear relationships. Missing values were imputed for DLCO by using the k-nearest neighbors’ method (impute.knn function) in the R package impute (version 1.60.0) and verified that imputation did not change centrality measures (e-Fig 1).
Centrality measures the importance of a node in a network in terms of connectivity. We used two commonly used measures of centrality that reflect both global and regional connectivity: that is, eigenvector and betweenness centrality, both calculated using igraph.\textsuperscript{19,20} Eigenvector centrality measures a node’s importance by considering both the direct connection to the node as well as the number of connections to its neighbors (connected nodes); as such, it measures the “reach” of the overall connections in a network. Because the network is enriched for cardiopulmonary unit metrics, eigenvector centrality will measure overall cardiopulmonary connections. It has the advantage of representing an overall cardiopulmonary centrality measure without preferentially selecting a specific metric. Betweenness centrality, conversely, quantifies the relative number of shortest paths passing through a specific node; as such, it will highlight nodes that connect directly to other nodes, similar to a hub between communication towers. A node that has both the highest eigenvector and betweenness centrality will usually occupy a central topology in a simple network. Nodes were color-coded by clinical domains, with size reflecting betweenness centrality. e-Table 1 summarizes the parameters included in the correlation network. Focused correlation matrices of highly connected variables are presented.

Cox proportional hazards regression was used for univariable and multivariable outcome analyses. A stepwise approach was used to develop a multivariable model. We first determined independent predictors from each cluster grouped according to eigenvector centrality tertiles. Parameters that were highly co-linear were excluded; for highly co-linear parameters, the choice of parameter was guided by its hazard ratio as well as by literature review (e-Table 2). We then assessed their incremental value in a multivariable analysis. Age, sex, connective tissue disease (CTD), and prostanoid therapy, as well as sodium, were also included for their known association with outcome in PAH. We used categorical or ordinal data because these are easier to translate in clinical practice; thresholds were based on previously studies or accepted laboratory reference values.\textsuperscript{19,20} Kaplan-Meier analysis was based on the Cox prognostic index. Alternate models were considered to account for potentially missing data in an imaging-focused model (without NT-proBNP or DLCO) and a biomarker-focused model (without imaging or DLCO). Although predefined thresholds were used, we also performed receiver-operating characteristic analysis with thresholds identified based on the Youden index as well as fixed 80% sensitivity and specificity.

For longitudinal analysis, we focused on the most central node of the network and evaluated its complementarity value to the baseline model. $P$ values < .05 were considered statistically significant. Analyses were performed by using R packages Hmisc (version 4.4-0) and igraph (version 1.2.5) and MedCalc Statistical Software version 19.6 (MedCalc Software Ltd.).

**Results**

**Study Population**

Of the 231 patients, 182 (79%) were female, and 73 (32%) had CTD. Median age was 48 years (38.6-57.3), MPAP was 50 ± 16 mm Hg, PVR indexed on body surface area was 19.2 (12.5-26.8) Wood units $\times \text{m}^2$, and the median NT-proBNP was 496 ng/L (120-1,507) (Table 1). Of the patients with CTD, 41 (56%) had scleroderma, 16 (22%) had systemic lupus erythematosus, 12 (16%) patients had mixed CTD or vasculitis, and five patients had rheumatoid arthritis (7%). No patients were in cardiogenic shock at the time of their echocardiography, although six patients were hypotensive (systolic BP < 90 mm Hg and cardiac index < 2 L/min/m$^2$ at the time of their right heart catheterization).

**Clinical Network in PAH**

We constructed an undirected network of clinical features in PAH (Fig 2). The network was enriched for echocardiographic parameters and included a total of 43 features (e-Table 1). NT-proBNP emerged as a central hub based on both eigenvector and betweenness centrality. Several echocardiographic parameters, including RVLS, RVESRI, and right atrial volume index, also had high eigenvector centrality. Among features with intermediate eigenvector centrality (second tertile), most notable were RAP, 6MWD, New York Heart Association functional class, and total bilirubin. Several other features had lower eigenvector centrality, including vital signs, markers of end-organ dysfunction (glomerular filtration rate [GFR], sodium, albumin, total bilirubin, hemoglobin, RBC distribution width), DLCO, and CTD etiology, as well as age and sex. In terms of topology, a shorter path length was observed between 6MWD, estimated GFR, and RBC distribution width and eRAP than with RV structural or functional indexes.

As expected, the network region surrounding NT-proBNP was densely populated with RV echocardiography parameters. A strong relationship was found between parameters of right heart size or function (Figs 3A, 3B). The relationship between two-dimensional measured TAPSE and other functional metrics was weaker, however. A nonlinear relationship was noted between NT-proBNP (log scale) and RVESRI (rho = 0.59; $P < .001$) as illustrated in Figure 3C. Among patients with eRAP $\geq 15$ mm Hg (n = 70), only three (4.2%) had normal RVESRI and NT-proBNP. On multivariable regression analysis, NT-proBNP was independently associated with RVESRI ($r$ partial = 0.38), eRAP ($r$ partial = 0.16), tricuspid regurgitation (TR) severity grade ($r$ partial = 0.35) and estimated GFR ($r$ partial = -0.19) with an $R^2$ of 0.46 ($P < .001$).

**Feature Connectivity and Outcome**

During a median follow-up time of 7.1 years (2.9-9.6 years), the combined outcome of death or lung transplantation occurred in 92 patients (39.8%) and
Table 1: Baseline Patient Characteristics

| Characteristic                        | Value          |
|---------------------------------------|----------------|
| Sample size                          | 231            |
| Demographic characteristics           |                |
| Age, y                                | 48.0 [38.6 to 57.3] |
| Female sex                           | 182 (78.8%)    |
| BMI, kg/m²                            | 26.7 [29.9 to 31.6] |
| Connective tissue disease–associated PAH | 73 (31.6%)     |
| Vital signs                           |                |
| Systolic BP, mm Hg                    | 113 [106 to 126] |
| Diastolic BP, mm Hg                   | 70 [63 to 77]  |
| Heart rate, beats/min                 | 81.0 [71.0 to 88.7] |
| Right heart catheterization           |                |
| Mean pulmonary arterial pressure, mm Hg | 50.1 ± 16.1    |
| Right atrial pressure, mm Hg          | 7.0 [5.0 to 11.8] |
| Pulmonary artery wedge pressure, mm Hg | 10.0 [8.0 to 13.0] |
| Cardiac index, L/min/m²               | 2.0 [1.67 to 2.35] |
| Pulmonary vascular resistance index, WU * m² | 19.2 [12.5 to 26.8] |
| Rel. pulmonary vascular resistance, % | 48.5 [33.3 to 0.61.5] |
| Echocardiographic data (selected)     |                |
| Relative RV end-systolic area         | 1.06 [0.67 to 1.51] |
| RV end-systolic remodeling index      | 1.47 [1.34 to 1.60] |
| RV lateral longitudinal strain, %     | -16.3% [-20.1 to -12.9] |
| Severe tricuspid regurgitation (3 to ≥4) | 51 (22%)       |
| Estimated RAP (eRAP)                  |                |
| 3 mm Hg (15%)                         |                |
| 8 mm Hg (54%)                         |                |
| ≥15 mm Hg (31%)                       |                |
| 20 mm Hg (9%)                         |                |
| Pericardial effusion (> 0.5 cm)       | 57 (25%)       |
| Left ventricular ejection fraction (%) | 60.7 [56.0 to 66.2] |
| Functional status                     |                |
| NYHA functional class                 |                |
| I                                     | 13 (5.6%)      |
| II                                    | 91 (39.4%)     |
| III                                   | 107 (46.3%)    |

Table 1 (Continued)

| Characteristic                          | Value          |
|-----------------------------------------|----------------|
| IV                                      | 20 (8.7%)      |
| 6MWD, m                                 | 429.8 [315.6 to 516.0] |
| Diffusing capacity of the lungs for carbon monoxide corrected for hemoglobin (% predicted) | 74.0% [60.0 to 87.0%] |
| Laboratory data                         |                |
| NT-proBNP, ng/L                         | 407 [100 to 1,300] |
| eGFR, mL/1.73 m²                        | 62.1 [49.1 to 74.1] |
| Albumin, g/L                            | 3.8 [3.4 to 4.0] |
| Sodium, mEq/L                           | 138 [136 to 140] |
| Hemoglobin, g/L                         | 14.0 [12.3 to 15.1] |
| RBC distribution width, %               | 14.9 [13.5 to 16.7] |
| HbA1C > 6.5%, %                         | 14 (6.1%)      |
| Comorbidities                           |                |
| Obesity (BMI > 30 kg/m²)                | 78 (33.8%)     |
| Diabetes mellitus                       | 14 (6.1%)      |
| Systemic hypertension                   | 13 (5.6%)      |
| Chronic kidney disease (eGFR < 45 mL/min/1.73 m²) | 33 (14.3%)    |
| Therapeutic consideration               |                |
| Incident cases (no PAH-specific therapy initiated) | 55 (23.8%)   |
| On prostanoid therapy                   | 82 (35.5%)     |
| Endothelin receptor antagonist          | 68 (29.4%)     |
| Phosphodiesterase-5 inhibitors          | 114 (49.4%)    |
| Spironolactone                          | 63 (27.2%)     |
| Anticoagulation                         | 44 (19.0%)     |

Data are presented as mean ± SD if normally distributed and as median [interquartile range] if not. 6MWD = 6-min walk distance; eGFR = estimated glomerular filtration rate; HbA1C = glycosylated hemoglobin; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; RAP = right atrial pressure; RV = right ventricular; WU = Wood unit.

Included 66 deaths and 26 lung transplantations. The 1- and 5-year event-free survival was 89% and 72%, respectively (Fig 4A). Hazard ratios were stable over the course of the study, with a strong association (r = 0.99) between 5-year and longer term outcome (Fig 4B). Of the 45 potential predictors, 33 were significantly associated with event-free survival on univariable analysis (e-Table 2). Among the echocardiographic parameters, RVESRI had the nominally highest
The absolute log2 transformed hazard ratio followed by TAPSE (two-dimensional)/RVSP ratio and right heart structural and functional parameters. Hazard ratios (absolute log2 transformed) were related to eigenvector centrality ($\rho = 0.42; P = .006$) but not betweenness centrality. This relationship was, however, far from linear (Fig 4C). For example, some features with high eigenvector centrality such as RVSP or PVRr had lower hazard ratios, whereas other features with low eigenvector centrality (eg, markers of end-organ dysfunction) had a higher hazard ratio.
Multivariable Cox Regression Model

To develop a multivariable outcome model, we used a stepwise approach according to centrality-based clusters (Table 2). Factors that emerged as independent in each cluster were then included in the final model. In selecting the parameters to consider, we avoided highly co-linear variables. For RV dimension, RVESRI was chosen because it is internally scaled, minimizing potential pseudo-normalization with obesity or fluid overload states (e-Table 2). The final model (Fig 5A) combined features with high (NT-proBNP and RVESRI), intermediate (6MWD), and lower (DLCO, systolic BP, albumin, sodium, sex, and CTD etiology) eigenvector centrality. This model provided good discrimination of outcome, with a Harrell’s C-index of 0.81 (0.77-0.85). Five risk strata were generated based on the normally distributed prognostic index (weighted sum of coefficients) and provided good separation of outcome as shown by the Kaplan-Meier curves (Fig 5B). e-Figure 2 shows Kaplan-Meier curves of the validated risk score. Sensitivity analysis was performed in patients with prevalent PAH and patients not on prostanoid therapy, which produced a Harrell’s C-index of 0.84 (0.80-0.88) and 0.75 (0.68-0.81), respectively. We also considered alternate models depending on available parameters; that is, an imaging-focused model (no NT-proBNP or DLCO) and a biomarker-focused model (no echocardiographic parameters or DLCO) (Table 3). Although the $\chi^2$ of these models was lower, the C-statistic for the 5-year outcome was not statistically different ($P = .10$ vs imaging-focused model and $P = .29$ vs laboratory-focused model).

Thresholds for Discrimination of Outcome

Using receiver-operating characteristic analysis, we assessed thresholds for the main outcome based on the Youden index and the fixed 80% sensitivity or specificity (Table 4). For the majority of parameters, including NT-proBNP, DLCO, and PVRr, values were consistent with commonly used thresholds in PAH or laboratory reference limits. For total bilirubin, however, a lower threshold was observed.

Serial Changes in NT-proBNP (Central Feature)

In 160 patients (69%), follow-up NT-proBNP values were available within 1 year. Thirty-eight percent of patients transitioned to a different NT-proBNP risk category at follow-up (Fig 5C). The low risk NT-proBNP
group remains the most stable over time, with 88% remaining in the same risk category. Serial changes in relative NT-proBNP (natural logarithmic scale) were associated with event-free survival (C-index of 0.64 [0.58-0.70]). When added to the baseline model, the C-statistic for 5-year outcome improved (from 0.78 [0.71-0.84] to 0.85 [0.78-0.90] corresponding to an increase in C-statistic of 0.071 ± 0.024; P = .0030) (Fig 5D), with Harrell’s C-index for long-term outcome improving from 0.75 (0.70-0.80) to 0.80 (0.75-0.84). Factors associated with relative change in NT-proBNP included CTD etiology (r partial = 0.18), hypoalbuminemia (r partial = 0.16), hyponatremia (r partial = 0.18), and NT-proBNP risk strata (r = -0.21).

Discussion
In the current study, network graph analysis not only identified NT-proBNP as a central hub in PAH but also provided explainability for risk stratification models. We found that risk prediction in PAH was best achieved by combining a small number of central right
heart features with less connected parameters reflecting functional capacity, end-organ dysfunction, and etiology. Moreover, risk was not static as shown by the serial NT-proBNP analysis.

One of the cornerstones of network analysis is the concept of centrality, which quantifies a node’s importance. Because this network was enriched with right atrial and right ventricular parameters, eigenvector centrality represented a global measure of right heart connectivity. It is therefore not surprising that eigenvector centrality was more strongly related to outcome than betweenness centrality. As an approach original to our study, we not only used centrality to identify a central hub but also to cluster parameters according to their connectivity.

NT-proBNP emerged as the central hub of our clinical network, with independent associations with RV dimension, right atrial pressure, and renal function. Nagaya et al. were the first to highlight the prognostic value of BNP at baseline and follow-up in PAH. More recently, using the REVEAL Registry, Frantz et al confirmed the value of baseline and follow-up NT-proBNP as a predictor of 5-year outcome. Consistent with these studies, we also found that baseline and serial changes in NT-proBNP were strongly related to event-free survival. Its reproducibility, availability, and strong prognostic value explains why BNP or NT-proBNP are included in the majority of risk scores in PAH.

In recent years, much attention has been focused on identifying prognostic imaging markers in PAH. Many indexes have been considered, including TAPSE, RV longitudinal strain, RV end-systolic dimension, RVEF, or, more recently, right atrial size or function or pulmonary artery pulsatility. Although most of these parameters have been strongly associated with event-free survival, recent studies highlight the value of RV end-systolic dimension. In fact, RV end-systolic dimension emerged as a strong marker of ventriculo-arterial coupling and adaptation and is sensitive to increases in afterload; in addition, RV dimensions are less likely to pseudo-normalize in the presence of severe TR. Few studies, however, have directly compared RV end-systolic dimension with RVLS or TAPSE. In the study of Ryo et al., RV end-systolic volume index quantified by using

| Cluster with Parameter Cluster-Based Analysis Multivariable Model |
|--------------------------|--------------------------|--------------------------|
| Higher centrality        | NT-proBNP < 300 ng/L     | 2.26 [1.23-4.15]         | 0.41 [0.22-0.75] |
|                          | [300-1,400] ng/dL        | 2.94 [1.54-5.56]         |                |
|                          | > 1,400 ng/L             | 2.51 [1.14-5.56]         | 2.78 [1.26-6.12] |
|                          | [1.35-1.70]              | 6.13 [2.51-14.94]        | 4.04 [1.67-9.77] |
|                          | > 1.70                   | 1.59 [1.00-2.52]         |                |
|                          | > 2/3                    |                          |                |
| Intermediate centrality  | eRAP > 15 mm Hg          | 1.93 [1.24-3.0]          |                |
|                          | NYHA functional class    | 1.79 [1.10-2.92]         |                |
|                          | 6MWD < 165 m             | 0.54 [0.34-0.85]         | 2.09 [1.05-4.19] |
|                          | > 445 m                  |                          |                |
| Lower centrality         | Resting HR > 92 beats/min| 1.65 [0.99-2.74]         | 3.09 [1.72-5.56] |
|                          | SBP < 100 mm Hg          | 3.86 [2.26-6.62]         |                |
|                          | eGFR < 45 mL/min/1.73 m² | 1.78 [1.10-2.87]         |                |
|                          | Sodium < 136 MEq/L       | 1.62 [1.01-2.62]         | 1.96 [1.22-3.15] |
|                          | Albumin < 3.5 g/L        | 2.08 [1.28-3.36]         | 1.89 [1.17-3.03] |
|                          | RDW > 15%                | 1.80 [1.14-2.85]         |                |
|                          | DLCO > 60%: < 80%        | 2.13 [1.36-3.34]         | 1.77 [1.09-2.85] |
| Demographic and etiology | Male sex                | ...                      | 1.74 [1.02-2.96] |
|                          | CTD                      | ...                      | 1.65 [0.98-2.78] |
|                          | Age (per 10 y)           | ...                      |                |
| Therapy                  | Prostanoid therapy       | 2.21 [1.46-3.33]         | 3.08 [1.94-4.89] |
|                          | Incident                | ...                      |                |
| C-index                  |                          | 0.81 [0.77-0.85]         |                |
| χ²                       |                          | 116                      |                |

The variables that emerged significant in each cluster were considered in the final multivariable model; age sex and CTD etiology were also included. 6MWD = 6-min walk distance; CTD = connective tissue disease; DLCO = diffusing lung capacity of carbon monoxide; eGFR = estimated glomerular filtration rate; eRAP = estimated right atrial pressure; HR = heart rate; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York Heart Association; PVR = pulmonary vascular resistance; RDW = RBC distribution width; RVESRI = right ventricular end-systolic remodeling indexed; SBP = systolic BP; SVR = systemic vascular resistance.
three-dimensional echocardiography was more predictive than RV global area strain. In addition, we have found that RVESRI was also more predictive than RVLS. Risk prediction does nor, howvever, rely on a single parameter in isolation. It is therefore not surprising, given the intertwined nature of connections in PAH, that other combinations may emerge across studies. For example, Fine et al has previously shown the incremental prognostic value of NT-proBNP and RVLS in a large study from the Mayo Clinic. More recently, Ghio et al also reported, using a pooled analysis, that TAPSE, TR severity, and inferior vena cava size were key features in defining risk. These studies show that different combination of right heart metrics may yield equivalent discrimination of outcome the choice of metric should be guide by center expertise and reproducibility of measures.

Our study also highlights the importance of markers of end-organ dysfunction. These markers are particularly useful for differentiating patients at intermediate and high risk of clinical worsening. For example, DLCO, which depends on both pulmonary blood flow and microvascular lung architecture, has been consistently associated with worse prognosis in PAH. Low DLCO

Figure 5 – A-D. Cox regression model in PAH. A, Independent parameters retained in the multivariable model. B, Kaplan-Meier transplant-free survival according to risk strata. C, Longitudinal changes in NT-proBNP within 1 year with 38% exhibiting a change in their NT-proBNP risk category (n = 160). D, Receiver-operating characteristic curves for the incremental value of serial changes in NT-proBNP when added to the baseline model (* indicates significant change in ROC). 6MWD = 6-min walk distance; Alb = albumin; CTD = connective tissue disease etiology; BNP = B-type natriuretic peptide; DLCO = diffusing lung capacity of carbon monoxide; Na = sodium; NT-proBNP = N-terminal pro-B type natriuretic peptide; PAH = pulmonary arterial hypertension; Peff = pericardial effusion; RVESRI = right ventricular end-systolic remodeling indexed; SBP = systolic BP; Tx = therapy.

base model 0.78 [0.71-0.84] + Serial NT-proBNP 0.85 [0.78-0.90] *
could additionally be found in patients with pulmonary venoocclusive disease, which also carries a worse prognosis.5 Similarly, as highlighted by the REVEAL and PHORA studies, impairment of BP regulation or renal, hepatic, or hematologic function is associated with increased mortality in PAH.2,3,6 The pathophysiology of

| TABLE 3 | Alternative Models Considering Different Data Availability |
|------------------|------------------|------------------|------------------|------------------|
| Cluster          | Parameter        | Imaging Focused  | Laboratory Focused |
| High centrality  | NT-proBNP < 300 ng/L | 3.97 [1.86-8.47] | 0.27 [0.15-0.47] |
|                  | RVESRI > 1.70    | 7.12 [3.12-16.27] |                |
| Intermediate centrality | eRAP > 15 mm Hg | 1.92 [1.02-3.62] |                |
| Lower centrality | 6MW > 165 m      | 2.16 [1.08-4.34] | 2.13 [1.07-4.26] |
|                  | SBP < 100 mm Hg  | 4.17 [2.33-7.47] | 3.18 [1.77-5.68] |
|                  | HR < 92 beats/min| 1.84 [1.12-3.03] |                |
|                  | Albumin < 3.5 g/L | 2.23 [1.39-3.57] | 2.14 [1.34-3.43] |
|                  | Sodium < 136 mEq/L| 2.19 [1.39-3.47] |                |
|                  | Dlco < 80%       |                |                |
|                  | Male sex         | 2.09 [1.23-3.55] | 1.94 [1.16-3.25] |
|                  | CTD              | 2.02 [1.21-3.37] | 1.87 [1.13-3.09] |
|                  | Prostanoid therapy| 2.49 [1.59-3.92] | 3.34 [2.12-5.25] |
|                  | C-index Full     | 0.78 [0.73-0.83] | 0.79 [0.75-0.83] |
| \( \chi^2 \)     | 107              | 98              |

The "..." indicates parameters not considered in the model. Imaging-focused models did not include NT-proBNP or Dlco. 6MW = 6-min walk distance; CTD = connective tissue disease; Dlco = diffusing lung capacity of carbon monoxide; eRAP = estimated right atrial pressure; HR = heart rate; NT-proBNP = N-terminal pro-B type natriuretic peptide; RVESRI = right ventricular end-systolic remodeling indexed; SBP = systolic BP.

| TABLE 4 | Receiver-Operating Curve Analysis and Associated Optimal and Fixed Sensitivity and Specificity Criteria |
|------------------|------------------|------------------|------------------|------------------|
| Parameter        | AUC              | Youden Index     | 80% Sensitivity  | 80% Specificity  |
|                  | Value (se, sp)   |                  | Value (sp)       | Value (se)       |
| NT-proBNP        | 0.72 (0.66-0.78) | 544 (74, 65)     | 398 (55)         | 1,363 (46)       |
| RVESRI           | 0.72 (0.66-0.78) | 1.47 (74, 61)    | 1.42 (48)        | 1.59 (48)        |
| RVESA ratio      | 0.72 (0.66-0.78) | 1.26 (62, 76)    | 0.89 (50)        | 1.4 (55)         |
| RVLS             | 0.64 (0.57-0.70) | -17.4 (77, 47)   | -18.3 (41)       | -12.8 (34)       |
| PVRr             | 0.60 (0.53-0.66) | 0.55 (50, 67)    | 0.34 (29)        | 0.62 (35)        |
| Dlco             | 0.66 (0.59-0.72) | 60 (44, 81)      | 82 (41)          | 62 (44)          |
| SBP              | 0.61 (0.55-0.68) | 99 (20, 97)      | 123 (30)         | 106 (37)         |
| HR               | 0.59 (0.53-0.66) | 87 (41, 77)      | 71 (31)          | 90 (30)          |
| 6MW              | 0.66 (0.59-0.72) | 409 (64, 62)     | 490 (35)         | 320 (41)         |
| eGFR             | 0.62 (0.55-0.68) | 62 (73, 47)      | 65 (36)          | 46 (36)          |
| Sodium           | 0.64 (0.58-0.70) | 136 (45, 75)     | 139 (37)         | 136 (40)         |
| Albumin          | 0.63 (0.56-0.69) | 3.5 (42, 81)     | 4.0 (32)         | 3.5 (43)         |
| Total bilirubin  | 0.64 (0.57-0.70) | 0.7 (51, 73)     | 0.2 (31)         | 0.9 (39)         |
| Hemoglobin Female| 0.61 (0.54-0.69) | 11.2 (31, 90)    | 14.6 (28)        | 11.8 (31)        |
| Male             | 0.71 (0.57-0.83) | 15.2 (67, 74)    | 16.5 (35)        | 14.5 (50)        |
| RDW              | 0.69 (0.63-0.75) | 14.9 (72.63)     | 14.6 (53)        | 16.9 (33)        |

se = sensitivity; sp = specificity; 6MW = 6-min walk distance; AUC = area under the curve; Dlco = diffusing lung capacity of carbon monoxide; eGFR = estimated glomerular filtration rate; HR = heart rate; NT-proBNP = N-terminal pro-B type natriuretic peptide; PVRr = relative pulmonary vascular resistance; RDW = RBC distribution width; RVESA = right ventricular end-systolic area; RVESRI = right ventricular end-systolic remodeling indexed; RVLS = right ventricular longitudinal strain; SBP = systolic BP.
end-organ dysfunction in PAH is complex, and several mechanisms such as neurohormonal activation, oxidative stress, and nutritional status may affect BP regulation, serum sodium, RBC distribution width, uric acid, or albumin.\textsuperscript{27-30} Disease trajectories are also important to consider in risk models. This has been incorporated in the REVEAL 2.0 by including recent all-cause hospitalization (≤ 6 months) as one of the predictive factors. As shown in the current study and others, serial changes in NT-proBNP (this study’s central feature) may also refine risk prediction.\textsuperscript{22}

Network graphs provide explainability for alternate models in PAH. For example, despite having few or no imaging parameters, multicenter risk scores achieve strong prediction of outcome. Consideration of the highly connected network is also important when evaluating novel biomarkers. For example, novel biomarkers need to be placed in the context of other routinely available biomarkers; in fact, co-linear biomarkers are unlikely to improve risk prediction (although they can provide invaluable mechanistic insights).\textsuperscript{31-33}

Taken together, clinicians often favor models in which complexity matches actionability. Feature selection in models should also be guided foremost by physiology but also informed by data architecture, its predictive ability, reliability, cost, risk, and availability for serial measurements. The simplest model would include demographic characteristics, etiology, functional class, health status, vital signs, laboratory data, and recent trajectories. Moreover, ongoing iteration of the PHORA models will continue to incorporate tolerance to missing data (or alternate feature selection) and use Bayesian network modeling approaches, thus providing a nuanced and pragmatic approach to risk stratification.\textsuperscript{6}

The current study has several limitations. First, this was a single-center study; the analysis, however, includes a comprehensive number of features and long-term follow-up. Second, although echocardiography, laboratory, and right heart catheterization data were not collected simultaneously in all participants, they were collected as part of a registry with representative nature of the data. We also verified that centrality was not affected by imputation of missing data (especially relevant for DLCO). Third, because oxygen consumption was assumed rather than directly measured, this likely affected the prognostic value of cardiac index. Finally, TAPSE was measured by using two-dimensional methods, which in our laboratory have excellent correlations with M-mode measurements.

**Interpretation**

Network graph analysis identified NT-proBNP as a central feature in PAH and provided explainability for risk stratification models in PAH.

---

**Acknowledgments**

**Author contributions:** F. H. takes responsibility for the content of the manuscript, including the data and analysis. F. H., K. C., T. K., R. T. Z., and A. S. designed the study. M. A. analyzed the echocardiographic data and provided critical revisions to the manuscript. All authors had full access to all the study data, take responsibility for the integrity of the data and the accuracy of the data analysis, and contributed substantially to the study design (analysis plan), data analysis, reporting, interpretation, and the writing of the manuscript.

**Financial/nonfinancial disclosures:** The authors have reported to CHEST the following: F. H. received past funding from Actelion Inc. on heart failure preserved ejection fraction phenotyping. None declared (K. C., M. A., A. Y. D., R. J. B., A. J., S. T., J. A. A., O. M., T. K., A. V., R. T., Z. A. J. S.).

**Role of sponsors:** The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

**Other contributions:** The authors thank the Stanford Cardiovascular Institute and the Stanford Wall Center for Pulmonary Vascular Disease for the study support.

**Additional information:** The e-Figures and e-Tables are available online under “Supplementary Data.”

**References**

1. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. *Ann Intern Med*. 1991;115:343-349.

2. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. *CHEST*. 2019;156:323-337.

3. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122:164-172.

4. Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. *Eur Respir J*. 2015;46:152-164.

5. Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J*. 2019;53:1-11.

6. Kanwar MK, Gomberg-Maitland M, Hoeper M, et al. Risk stratification in pulmonary arterial hypertension using Bayesian analysis. *Eur Respir J*. 2020;1-11.

7. Raina A, Humbert M. Risk assessment in pulmonary arterial hypertension. *Eur Respir Rev*. 2016;25:390-398.

8. Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. *Eur Respir J*. 2019;53:1-13.
12. Ghio S, Mercurio V, Fortuni F, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. *Circ Cardiovasc Imaging*. 2013;6:711-721.

10. Amsallem M, Sweatt AJ, Aymami MC, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: comparison with validated models. *Circ Cardiovasc Imaging*. 2017;10:1-13.

11. Stepnowska E, Lewicka E, Dabrowska-Kugacka A, et al. Predictors of poor outcome in patients with pulmonary arterial hypertension: a single center study. *PLoS One*. 2018;13:e0193245.

12. Ghio S, Mercurio V, Fortuni F, et al. TAPSE in PAH Investigators. A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. *Eur Respir J*. 2020;56:1-10.

13. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med*. 2006;174:1034-1041.

14. Deo RC. Machine learning in medicine. *Circulation*. 2015;132:1920-1930.

15. Kobayashi Y, Tremblay-Gravel M, et al. Network analysis to risk stratify patients with heart failure preserved ejection fraction. *Sci Rep*. 2019;9:1-10.

16. Oldham WM, Oliveira RKF, Wang RS, et al. Network analysis to risk stratify patients with exercise intolerance. *Circ Res*. 2018;122:864-876.

17. Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22:523-529.

18. Grafton G, Cascino TM, Perry D, et al. Resting oxygen consumption and heart failure: importance of measurement for determination of cardiac output with the use of the fick principle. *J Card Fail*. 2019;15:664-672.

19. Brandes U. A faster algorithm for betweenness centrality. *J Mathematical Sociol*. 2001;25(2):163-177.

20. Bonacich P. Power and centrality: a family of measures. *Am J Sociology*. 1987;92:1170-1182.

21. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102:665-670.

22. Frantz RP, Farber HW, Badesch DB, et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL Registry. *Chest*. 2018;154:126-135.

23. van de Veerdonk MC, Marcus JT, Westerhof N, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. *Chest*. 2015;147:1063-1071.

24. Swift AJ, Capener D, Johns C, et al. Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2017;196:228-239.

25. Ryo K, Goda A, Onishi T, et al. Characterization of right ventricular remodeling in pulmonary hypertension associated with patient outcomes by 3-dimensional wall motion tracking echocardiography. *Circ Cardiovasc Imaging*. 2015;8:1-9.

26. Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. *J Heart Lung Transplant*. 2010;29:181-187.

27. Hampole CV, Mehrotra AK, Thenappan T, Gomberg-Maitland M, Shah SJ. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol*. 2009;104:868-872.

28. Rhodes CJ, Wharton J, Howard LS, Gibbs JS, Wälkın MR. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*. 2011;97:1054-1060.

29. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. *Am J Cardiol*. 2005;95:199-203.

30. Allen LA, Felker GM, Mhira MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. *J Card Fail*. 2010;16:230-238.

31. Giannitsis E, Mueller-Hennessen M, Katus HA. Aptamer-based proteomic profiling for prognostication in pulmonary arterial hypertension. *Lancet Respir Med*. 2017;5:671-672.

32. Sweatt AJ, Hedlin HK, Balasubramanian V, et al. Discovery of distinct immune phenotypes using machine learning in pulmonary arterial hypertension. *Circ Res*. 2019;124:904-919.

33. Amsallem M, Sweatt AJ, Arthur Aataam J, et al. Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. *Eur Respir J*. 2020;1-13.

chestjournal.org 1359